Today, the US FDA approved Erleada (apalutamide), an androgen receptor inhibitor created by Janssen Pharmaceuticals for the treatment of men with non-metastatic, castration-resistant prostate cancer. Erleada was approved after a priority review of...

In this blog PCRI presents an interview from our contributing partner, Prostatepedia. 

Prostatepedia spoke with Dr. Charles G. Drake at length about current trends in immunotherapy for prostate cancer. Here is the interview:

In this blog PCRI presents an interview from our contributing partner, Prostatepedia. 

Mr. Jeff Lee, a mobile technology veteran, develops clinical trial apps for most major pharmaceutical companies. Prostatepedia spoke with him about how mobile technology streamlines the clinical trial experience for both patients and researchers alike. Here is the interview:

Mark Moyad, MD is a best-selling author and an authority on alternative treatments. In this much-requested article, Dr. Moyad analyzes clinical data and definitively answers common questions about the efficacy of Marijuana on cancer and cancer-related side effects. 

A new oral medication called ARAMIS is being evaluated in men who have rising PSA levels on Lupron and whose bone scans remain clear. For more information, visit: https://clinicaltrials.gov/show/NCT02200614

ARAMIS is similar to Xtandi but may have some advantages because ARAMIS is less likely to affect brain function which could reduce the likelihood of seizures and side effects...

Interpreting a Pathology Report By Jonathan Epstein, MD | Johns Hopkins University

Patients should personally review their pathology report; the expert description of the information obtained from the needle biopsy. In this article, Dr. Epstein answers 15 common questions about understanding a pathology report.

Bob Each shares the inspiring story of his prostate cancer journey and some practical ideas about living with the disease.